Clinical Trial Update: Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects [Phase 1]

View source ↗

Summary

This Phase 1 dose-escalation study evaluated a single subcutaneous dose of NNC 0113-0217 in healthy male volunteers to assess safety, tolerability, pharmacokine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NNC 0113-0217

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED